Location History:
- Middletown, CT (US) (2006)
- Princeton Junction, NJ (US) (2012)
Company Filing History:
Years Active: 2006-2012
Title: Reginald O Cann: Innovator in Pharmaceutical Chemistry
Introduction
Reginald O Cann is a notable inventor based in Princeton Junction, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds that serve as inhibitors for various biological processes. With a total of 2 patents to his name, his work has implications for treating diseases that require specific therapeutic interventions.
Latest Patents
One of Reginald O Cann's latest patents focuses on "Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors." This patent presents novel compounds that act as 11-beta-hydroxysteroid dehydrogenase type I inhibitors, which are useful in treating, preventing, or slowing the progression of diseases that necessitate this type of therapy. The compounds described in this patent include specific formulas and their stereoisomers or pharmaceutically acceptable salts.
Another significant patent involves a "Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors." This process outlines the preparation of a pyrrolotriazine aniline p38 kinase inhibitor through the direct aminolysis of an ester, utilizing strong organometallic bases and specific amines to yield the desired amide.
Career Highlights
Reginald O Cann is currently associated with Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His work at this esteemed organization has allowed him to focus on innovative solutions in drug development and therapeutic applications.
Collaborations
Throughout his career, Reginald has collaborated with notable colleagues, including Jun Li and Jeffrey A Robl. These collaborations have contributed to the advancement of research and development in the pharmaceutical sector.
Conclusion
Reginald O Cann's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an innovator in the field. His work continues to impact the development of therapies that address critical health challenges.